Clinical Trial

Psychopharmacotherapy for Depressive Patients

Study acronym: BMDD-2022
Recruiting
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to compare the short (12 week) and long-term (1-year) efficacy and the tolerability between stepwise psychopharmacotherapy and antidepressant monotherapy for 12 weeks in adult patients with major depressive disorders, stratified by the multimodal serum biomarker scores.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-09-19; most recent amendment 2024-04-16.
Trial Details
NCT Number NCT06054321
Lead Sponsor Chonnam National University Hospital
Conditions Major Depressive Disorder
Enrollment 400 participants
Start Date 2022-08-03
Primary Completion 2028-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-04-18